# Abata Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/abata-therapeutics

- Industry: Biotechnology
- Headquarters: Watertown, US
- Website: www.abatatx.com/
- Total disclosed funding: $45M
- Latest round: Series A (Jun 23, 2021)
- Investors on record: 6

## About

Established in 2021 by Richard Ransohoff (CMO) and others and based in Massachusetts, US, Abata Therapeutics, Inc. operates as a developer of cell therapy by using regulatory T cells to treat serious autoimmune and inflammatory diseases. The company was launched by Third Rock Ventures. In August 2024, Abata Therapeutics, Inc. raised venture funding from Celgene. As of 2024, the company is led by its CEO and president, Samantha Singer.

The company develops tissue-specific therapies for autoimmune diseases, focusing on conditions with unmet needs such as progressive multiple sclerosis (MS) and type 1 diabetes (T1D). The firm's lead program targets progressive MS, which is a debilitating autoimmune disease that damages the central nervous system (CNS). Abata’s TCR-Treg therapy addresses the core pathology of MS, where existing treatments fall short by selectively targeting and modulating the immune response.

In addition, the company is advancing a program for T1D, targeting patients with a specific genetic HLA haplotype. This program aims to intervene early in the disease process to preserve beta-cell function and prevent the onset of insulin dependence.

The organization plans to use the August 2024 funding to support the development of its ABA-101 to treat sclerosis.

## Funding rounds

- Series A, Jun 23, 2021, $45M — Lightspeed Venture Partners, Invus [DUP], Third Rock Ventures, JDRF T1D Fund, Samsara BioCapital, ElevateBio, LLC

## Investors

- Lightspeed Venture Partners (https://capitalatlas.ai/funds/lightspeed-venture-partners) — Series A
- Invus [DUP] — Series A
- Third Rock Ventures (https://capitalatlas.ai/funds/third-rock-ventures) — Series A
- JDRF T1D Fund (https://capitalatlas.ai/funds/jdrf-t1d-fund) — Series A
- Samsara BioCapital (https://capitalatlas.ai/funds/samsara-biocapital) — Series A
- ElevateBio, LLC — Series A